Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have dramatically altered the treatment landscape of advanced non small cell lung cancer (NSCLC). While monotherapy and chemo-immunotherapy combinations are widely…
Biomarkers and Dual Checkpoint Blockade in Advanced Non Small Cell Lung Cancer Survival
